J Med Genet

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Journal of Medical Genetics 2008;45:63-64; doi:10.1136/jmg.2007.054700
Copyright © 2008 by the BMJ Publishing Group Ltd.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Evans, D G
Right arrow Articles by Narod, S A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Evans, D G
Right arrow Articles by Narod, S A
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Genetics Home Reference

POSTSCRIPT

Correspondence

Is CHEK2 a cause of the Li–Fraumeni syndrome?

D G Evans1, J M Birch2, S A Narod3

1 Academic Unit of Medical Genetics and Regional Genetics Service, St Mary’s Hospital, Manchester, UK
2 CR-UK Paediatric and Familial Cancer Research Group, Royal Manchester Children’s Hospital, Manchester, UK
3 Centre for Research in Women’s Health, Women’s College Hospital, Toronto, Ontario, Canada

Correspondence to:
Professor D G Evans, Academic Unit of Medical Genetics & Regional Genetics Service, St Mary’s Hospital, Hathersage Road, Manchester, M13 0JH, UK; gareth.evans@cmmc.nhs.uk]

The first 150 words of the full text of this article appear below.

We have reviewed the evidence for CHEK2 as a cause of Li–Fraumeni syndrome (LFS) in view of the continued debate about the cancer spectrum associated with mutations in this gene.1 In 1969 Li and Fraumeni reported four families with an autosomal dominant predisposition to a range of cancer types in children and young adults, including soft tissue sarcoma and breast cancer.2 In 1988, they extended their analysis to 24 families to characterise better the phenotype of the syndrome.3 These families contained greater than expected numbers of soft tissue sarcomas, osteosarcomas, breast cancers, childhood adrenocortical carcinomas, brain tumours and leukaemia. This group of cancers was soon accepted as the formal criteria for the clinical definition of classical LFS (box 1).


Box 1
Li–Fraumeni syndrome (LFS) criteria
  1. Proband with any bone or soft tissue sarcoma, diagnosed under the age of 45 years
  2. one first degree relative with cancer under 45 years of age
  3. and one first or . . . [Full text of this article]

 






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 by the BMJ Publishing Group Ltd.